US › Healthcare

Lyell Immunopharma Inc (LYEL)

US · Healthcare · Biotechnology

$14.86-0.93%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$3,000

Revenue YoY

-80.0%

Net profit

$-45.5M

EPS

$-1.86

EPS estimate

$-2.06

Net margin

-1,517,633.3%

EPS came in at -1.86 against a street estimate of -2.06 — a beat of 9.7%.

Key statistics

Market cap

$378.1M

Forward P/E

0.0

P/B

1.13

Book value

$11.68

EPS (TTM)

$-12.86

52-week high

$45.00

52-week low

$7.20

50-day MA

$10.85

200-day MA

$16.74

Beta

-0.09

Analyst view

Analysts rate Lyell Immunopharma Inc a buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $37.88.

Shareholding

Insiders

37.31%

Institutions

54.35%

Largest institutional holders

Fund	Stake
ARCH VENTURE CORP	13.25%
GSK PLC	6.17%
Vanguard Capital Management, LLC	3.21%
Orland Properties Ltd	3.08%
BlackRock Inc	2.96%
Almitas Capital LLC	2.37%
Foresite Capital Management V, LLC	1.94%
Millennium Management LLC	1.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lyell Immunopharma Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.